Evidence map›Paper›PMID 38259411›Full record

ArticleCureus2023

Response to Immunotherapy in Sclerosing Epithelioid Fibrosarcoma: Case Report and Literature Review.

Anna S Koerner, Maggie Zhou, Ashley Brook, Sam S Yoon, Kristen N Ganjoo

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Anna S KoernerSurgical Oncology, Surgery, Columbia University Irving Medical Center, New York, USA.
Maggie ZhouHematology and Medical Oncology, Stanford University School of Medicine, Stanford, USA.
Ashley BrookHematology and Medical Oncology, Stanford University School of Medicine, Stanford, USA.
Sam S YoonSurgical Oncology, Surgery, Columbia University Irving Medical Center, New York, USA.
Kristen N GanjooHematology and Medical Oncology, Stanford University School of Medicine, Stanford, USA.
Columbia University Irving Medical Center · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
HIFs and VEGF in sarcoma progression, metastasis, and radiation responseR01CA158301 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SIMON, M. CELESTE, YOON, SAM SUNGHYUN · 2011 to 2021
$4.1M
NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA158301
6 · The paper itself

Abstract

Sclerosing epithelioid fibrosarcoma (SEF) is an extremely rare subtype of sarcoma that appears histologically low-grade yet usually has a clinically aggressive course with a high rate of local recurrence and distant metastasis. However, these recurrences and metastases often occur years after initial treatment. Metastases can be to the lung as well as extra-pulmonary sites. In this case report, we discuss a patient who developed SEF in the deep soft tissue with metastases. This patient underwent checkpoint inhibitor therapy, with disease response. Thus, SEF is a sarcoma subtype with a unique tumor biology, and immunotherapy may be a promising avenue for treatment.

Indexed as

ipilimumabnivolumabpazopanibpembrolizumabsarcomasclerosing epithelioid fibrosarcoma

Identifiers

PMID38259411
PMCPMC10801283
OpenAlexW4390096564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.